Formosa Pharmaceuticals (TPE:6838) signed an exclusive licensing deal with South Korea's Samil Pharmaceutical (KRX:000520) for commercialization rights of its ophthalmic drug clobetasol propionate suspension (APP13007) in Vietnam.
The agreement covers treatment for post-operative eye inflammation and pain, with financial terms including upfront payments, milestones and royalties, according to a Thursday Taiwan Exchange filing.
Formosa said the Vietnam eye care market offers steady growth, and the deal is expected to support future sales and business development.
Deal details, however, remain confidential.